Evidence map›Paper›PMID 34025415›Full record

ArticleFrontiers in pharmacology2021

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study.

Xin Li, Jie Huang, Yao Qiu, Qianyun Zhang, Shaoyu Yang, Kan Wu, Jiaoli Wang, Limin Wang, Jian Ye, Shenglin Ma and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Xin LiDepartment of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jie HuangDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yao QiuDepartment of Thoracic Oncology, Nanjing Medical University Affiliated Hangzhou Hospital, Hangzhou, China.
Qianyun ZhangDepartment of Thoracic Oncology, Nanjing Medical University Affiliated Hangzhou Hospital, Hangzhou, China.
Shaoyu YangDepartment of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Kan WuDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiaoli WangDepartment of Respiratory Disease, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Limin WangDepartment of Respiratory Disease, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jian YeDepartment of Respiratory Disease, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shenglin MaDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Bing XiaDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xueqin ChenDepartment of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hangzhou First People's Hospital · CNNanjing Medical University · CNZhejiang University · CNHangzhou Cancer Hospital · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in the treatment of advanced non-small-cell lung cancer (NSCLC), bevacizumab plus platinum-based doublet chemotherapy remains a commonly used first-line regimen. This study was conducted to compare the efficacy and safety of pemetrexed-platinum with or without bevacizumab in Chinese chemo-naive advanced lung adenocarcinoma patients in a real-world setting. We retrospectively collected 100 patients who received pemetrexed-platinum with or without bevacizumab (PP,

Indexed as

adrenal metastasisbevacizumablung adenocarcinomapemetrexedplatinum

Identifiers

PMID34025415
PMCPMC8138310
OpenAlexW3158518943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.